|
1
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK,
Govindan R, et al: Non-small cell lung cancer. J Natl Compr Canc
Netw. 10:1236–1271. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R,
Grannis FW Jr, et al: Non-small cell lung cancer, version 2.2013. J
Natl Compr Canc Netw. 11:645–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goeckenjan G, Sitter H, Thomas M,
Branscheid D, Flentje M, Griesinger F, Niederle N, Stuschke M, Blum
T, Deppermann KM, et al: Prevention, diagnosis, therapy, and
follow-up of lung cancer: Interdisciplinary guideline of the German
Respiratory Society and the German Cancer Society. Pneumologie.
65:39–59. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alberg AJ, Brock MV, Ford JG, Samet JM and
Spivack SD: Epidemiology of lung cancer: Diagnosis and management
of lung cancer, 3rd ed: American College of Chest Physicians
evidence-based clinical practice guidelines. Chest. 143 Suppl
5:e1S–e29S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayat MJ, Howlader N, Reichman ME and
Edwards BK: Cancer statistics, trends, and multiple primary cancer
analyses from the surveillance, epidemiology, and end results
(SEER) program. Oncologist. 12:20–37. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mountain CF: Revisions in the
international system for staging lung cancer. Chest. 111:1710–1717.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lorent N, De Leyn P, Lievens Y, Verbeken
E, Nackaerts K, Dooms C, Van Raemdonck D, Anrys B and Vansteenkiste
J: Leuven Lung Cancer Group: Long-term survival of surgically
staged IIIA-N2 non-small cell lung cancer treated with a surgical
combined modality approach: Analysis of a 7-year prospective
experience. Ann Oncol. 15:1645–1653. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Casali C, Stefani A, Natali P, Rossi G and
Morandi U: Prognostic factors in surgically resected N2 non-small
cell lung cancer: The importance of patterns of mediastinal lymph
nodes metastases. Eur J Cardiothorac Surg. 28:33–38. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Andre F, Grunenwald D, Pignon JP, Dujon A,
Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V and Le
Chevalier T: Survival of patients with resected N2 non-small cell
lung cancer: Evidence for a subclassification and implications. J
Clin Oncol. 18:2981–2989. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suzuki K, Nagai K, Yoshida J, Nishimura M,
Takahashi K and Nishiwaki Y: The prognosis of surgically resected
N2 non-small cell lung cancer: The importance of clinical N status.
J Thorac Cardiovasc Surg. 118:145–153. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Douillard JY, Rosell R, De Lena M,
Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR,
Le Groumellec A, Lorusso V, et al: Adjuvant vinorelbine plus
cisplatin versus observation in patients with completely resected
stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine
International Trialist Association [ANITA]): A randomised
controlled trial. Lancet Oncol. 7:719–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arriagada R, Bergman B, Dunant A, Le
Chevalier T, Pignon JP and Vansteenkiste J: International Adjuvant
Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-small-cell
lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Le Péchoux C: Role of postoperative
radiotherapy in resected non-small cell lung cancer: A reassessment
based on new data. Oncologist. 16:672–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
No authors listed: Postoperative
radiotherapy in non-small-cell lung cancer: Systematic review and
meta-analysis of individual patient data from nine randomised
controlled trials. PORT Meta-analysis Trialists Group. Lancet.
352:257–263. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bekelman JE, Rosenzweig KE, Bach PB and
Schrag D: Trends in the use of postoperative radiotherapy for
resected non-small-cell lung cancer. Int J Radiat Oncol Biol Phys.
66:492–499. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Uno T, Sumi M, Kihara A, Numasaki H,
Kawakami H, Ikeda H, Mitsumori M and Teshima T: Japanese PCS
Working Subgroup of Lung Cancer: Postoperative radiotherapy for
non-small-cell lung cancer: Results of the 1999–2001 patterns of
care study nationwide process survey in Japan. Lung Cancer.
56:357–362. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lally BE, Zelterman D, Colasanto JM,
Haffty BG, Detterbeck FC and Wilson LD: Postoperative radiotherapy
for stage II or III non-small-cell lung cancer using the
surveillance, epidemiology, and end results database. J Clin Oncol.
24:2998–3006. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Le Péchoux C, Dunant A, Pignon JP, De
Ruysscher D, Mornex F, Senan S, Casas F, Price A and Milleron B:
Need for a new trial to evaluate adjuvant postoperative
radiotherapy in non-small cell lung cancer patients with N2
mediastinal involvement. J Clin Oncol. 25:e10–e11. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Yu XL, Zheng GF and Zhao F:
Intensity-modulated radiotherapy and volumetric-modulated arc
therapy have distinct clinical advantages in non-small cell lung
cancer treatment. Med Oncol. 32:942015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Douillard JY, Rosell R, De Lena M, Riggi
M, Hurteloup P and Mahe MA: Adjuvant Navelbine International
Trialist Association: Impact of postoperative radiation therapy on
survival in patients with complete resection and stage I, II, or
IIIA non-small cell lung cancer treated with adjuvant chemotherapy:
The adjuvant Navelbine international trialist association (ANITA)
randomized trial. Int J Radiat Oncol Biol Phys. 72:695–701. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lally BE, Zelterman D, Colasanto JM,
Haffty BG, Detterbeck FC and Wilson LD: Postoperative radiotherapy
for stage II or III non-small cell lung cancer using the
surveillance, epidemiology, and end results database. J Clin Oncol.
24:2998–3006. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rusch VW, Asamura H, Watanabe H, Giroux
DJ, Rami-Porta R and Goldstraw P: Members of IASLC Staging
Committee: The IASLC lung cancer staging project: A proposal for a
new international lymph node map in the forthcoming seventh edition
of the TNM classification for lung cancer. J Thorac Oncol.
4:568–577. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Higgins KA, Chino JP, Berry M, Ready N,
Boyd J, Yoo DS and Kelsey CR: Local failure in resected N1 lung
cancer: Implications for adjuvant therapy. Int J Radiat Oncol Biol
Phys. 83:727–733. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Varlotto JM, Yao AN, DeCamp MM,
Ramakrishna S, Recht A, Flickinger J, Andrei A, Reed MF, Toth JW,
Fizgerald TJ, et al: Nodal stage of surgically resected non-small
cell lung cancer and its effect on recurrence patterns and overall
survival. Int J Radiat Oncol Biol Phys. 91:765–773. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim KJ, Ahn YC, Lim DH, Han J, Park K,
Park JO, Kim K, Kim J and Shim YM: Analyses on prognostic factors
following tri-modality therapy for stage IIIa non-small cell lung
cancer. Lung Cancer. 55:329–336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Casali C, Stefani A, Natali P, Rossi G and
Morandi U: Prognostic factors in surgically resected N2 non-small
cell lung cancer: The importance of patterns of mediastinal lymph
nodes metastasis. Eur J Cardiothorac Surg. 28:33–38. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zou B, Xu Y, Li T, Li W, Tang B, Zhou L,
Li L, Liu Y, Zhu J, Huang M, et al: A multicenter retrospective
analysis of survival outcome following postoperative
chemoradiotherapy in non-small-cell lung cancer patients with N2
nodal disease. Int J Radiat Oncol Biol Phys. 77:321–328. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Patel SH, Ma Y, Wernicke AG, Nori D, Chao
KS and Parashar B: Evidence supporting contemporary post-operative
radiation therapy (PORT) using linear accelerators in N2 lung
cancer. Lung Cancer. 84:156–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Billiet C, Decaluwé H, Peeters S,
Vansteenkiste J, Dooms C, Haustermans K, De Leyn P and De Ruysscher
D: Modern post-operative radiotherapy for stage III non-small cell
lung cancer may improve local control and survival: A
meta-analysis. Radiother Oncol. 110:3–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Corso CD, Rutter CE, Wilson LD, Kim AW,
Decker RH and Husain ZA: Re-evaluation of the role of postoperative
radiotherapy and the impact of radiation dose for non-small-cell
lung cancer using the National Cancer Database. J Thora Oncol.
10:148–155. 2015. View Article : Google Scholar
|
|
32
|
Finn CF, Pechoux CL, Edwards J and Lunt C:
189: Lung ART: Phase III study comparing post-operative conformal
radiotherapy to no post-operative radiotherapy in patients with
completely resected non-small cell lung cancer and mediastinal N2
involvement. Lung Cancer. 87 Suppl 1:S70–S71. 2015. View Article : Google Scholar
|
|
33
|
Ou SH, Zell JA, Ziagos A and Anton-Culver
H: Prognostic significance of the non-size-based AJCC T2
descriptors: Visceral pleura invasion, hilar atelectasis, or
obstructive pneumonia in stage IB non-small cell lung cancer is
dependent on size. Chest. 133:662–669. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsuchiya T, Hashizume S, Akamine S,
Muraoka M, Honda S, Tsuji K, Urabe S, Hayashi T, Yamasaki N and
Nagayasu T: Upstaging by vessel invasion improves the pathology
staging system of non-small cell lung cancer. Chest. 132:170–177.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yilmaz A, Duyar SS, Cakir E, Aydin E,
Demirag F, Karakaya J, Yazici U and Erdogan Y: Clinical impact of
visceral pleural, lymphovascular and perineural invasion in
completely resected non-small cell lung cancer. Eur J Cardiothorac
Surg. 40:664–670. 2011.PubMed/NCBI
|
|
36
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wei S, Asamura H, Kawachi R, Sakurai H and
Watanabe S: Which is the better prognostic factor for resected
non-small cell lung cancer: The number of metastatic lymph nodes or
the currently used nodal stage classification? J Thorac Oncol.
6:310–318. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee JG, Lee CY, Park IK, Kim DJ, Park SY,
Kim KD and Chung KY: Number of metastatic lymph nodes in resected
non-small cell lung cancer predicts patient survival. Ann Thorac
Surg. 85:211–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
